[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Bernard Coulie Biography and Net Worth

CEO of Pliant Therapeutics

Pliant CEO Bernard Coulie, M.D., Ph.D., brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Dr. Coulie held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie serves as the Independent Chairman of the Board of Directors at Calypso Biotech, a privately-held biotechnology company based in the Netherlands and is a member of the Board of Directors of SQZ Biotechnologies, a publicly-traded cell therapy biotechnology company.

Dr. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium. He is a board-certified internist and holds an MBA from the Vlerick Management School, Leuven, Belgium.

What is Bernard Coulie's net worth?: The estimated net worth of Bernard Coulie is at least $6.00 million as of July 10th, 2024. Dr. Coulie owns 482,936 shares of Pliant Therapeutics stock worth more than $6,002,894 as of November 17th. This net worth evaluation does not reflect any other investments that Dr. Coulie may own. Additionally, Dr. Coulie receives a salary of $996,970.00 as CEO at Pliant Therapeutics. Learn More about Bernard Coulie's net worth.
How old is Bernard Coulie?: Dr. Coulie is currently 57 years old. There are 4 older executives and no younger executives at Pliant Therapeutics. Learn More on Bernard Coulie's age.
What is Bernard Coulie's salary?: As the CEO of Pliant Therapeutics, Inc., Dr. Coulie earns $996,970.00 per year. Learn More on Bernard Coulie's salary.
How do I contact Bernard Coulie?: The corporate mailing address for Dr. Coulie and other Pliant Therapeutics executives is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. Pliant Therapeutics can also be reached via phone at 650-481-6770 and via email at [email protected]. Learn More on Bernard Coulie's contact information.
Has Bernard Coulie been buying or selling shares of Pliant Therapeutics?: Bernard Coulie has not been actively trading shares of Pliant Therapeutics within the last three months. Most recently, Bernard Coulie sold 38,710 shares of the business's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $11.56, for a transaction totalling $447,487.60. Following the completion of the sale, the chief executive officer now directly owns 482,936 shares of the company's stock, valued at $5,582,740.16. Learn More on Bernard Coulie's trading history.
Who are Pliant Therapeutics' active insiders?: Pliant Therapeutics' insider roster includes Bernard Coulie (CEO), and Eric Lefebvre (Insider). Learn More on Pliant Therapeutics' active insiders.
Are insiders buying or selling shares of Pliant Therapeutics?: In the last year, insiders at the sold shares 8 times. They sold a total of 120,081 shares worth more than $1,674,386.31. The most recent insider tranaction occured on July, 10th when insider Eric Lefebvre sold 12,319 shares worth more than $142,407.64. Insiders at Pliant Therapeutics own 6.4% of the company. Learn More about insider trades at Pliant Therapeutics.
Information on this page was last updated on 7/10/2024.

Bernard Coulie Insider Trading History at Pliant Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/10/2024	Sell	38,710	$11.56	$447,487.60	482,936
1/17/2024	Sell	25,721	$17.23	$443,172.83	316,382
7/17/2023	Sell	70,150	$18.01	$1,263,401.50	342,103
3/30/2023	Sell	35,339	$26.52	$937,190.28	274,753
2/3/2023	Sell	15,000	$33.61	$504,150.00	240,112
1/31/2023	Sell	15,000	$34.92	$523,800.00	240,112
1/26/2023	Sell	15,000	$35.29	$529,350.00	240,112
1/24/2023	Sell	15,000	$30.89	$463,350.00	93,812
1/9/2023	Sell	5,000	$19.17	$95,850.00	93,812
1/6/2023	Sell	15,000	$19.04	$285,600.00	93,812
1/3/2023	Sell	15,000	$19.33	$289,950.00	93,812
12/20/2022	Sell	34,212	$19.10	$653,449.20	93,812
9/12/2022	Sell	12,502	$22.54	$281,795.08	59,273
7/11/2022	Sell	15,000	$22.50	$337,500.00	59,273
6/14/2021	Sell	4,000	$33.03	$132,120.00	54,840
5/14/2021	Sell	3,500	$28.64	$100,240.00	54,840
4/14/2021	Sell	3,500	$30.33	$106,155.00	54,840
3/15/2021	Sell	3,500	$38.52	$134,820.00	48,840
1/14/2021	Sell	3,500	$26.38	$92,330.00	48,840
12/14/2020	Sell	3,500	$27.37	$95,795.00	48,840

Bernard Coulie Buying and Selling Activity at Pliant Therapeutics

Pliant Therapeutics Company Overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $12.43

$11.76

$12.90

50 Day Range

MA: $13.08

$10.55

$15.70

2 Week Range

Now: $12.43

$10.22

$19.62

Volume

741,228 shs

Average Volume

401,670 shs

Market Capitalization

$756.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

[Urgent] Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

Click here now for the urgent details on this hidden play.

Bernard Coulie Biography and Net Worth

What is Bernard Coulie's net worth?

How old is Bernard Coulie?

What is Bernard Coulie's salary?

How do I contact Bernard Coulie?

Has Bernard Coulie been buying or selling shares of Pliant Therapeutics?

Who are Pliant Therapeutics' active insiders?

Are insiders buying or selling shares of Pliant Therapeutics?